



**15** YRS  
2005-2020  
**GALLIPOLI**  
MEDICAL RESEARCH FOUNDATION  
Remembrance through research

# Gallipoli Medical Research Foundation **ANNUAL REPORT 2019-2020** *Remembrance through Research*

# Contents

3	Message from the Chairman Liam Kelly
4	Message from the CEO Miriam Dwyer
5	Message from the Director of Research Prof Darrell Crawford
6	GMRF Profile & Strategy
8	Veteran Health Research
11	Liver Research
14	Respiratory Research
15	Affiliated Research
16	Clinical Trials Unit
17	GMRF Innovation Grants
18	GMRF PhD Scholarship Program
21	GPH Cancer Wellness Program
20	Board of Directors
28	Patrons & Ambassadors
30	Committees
31	Acknowledgments
34	Financial Highlights 2019-2020
35	Supporting GMRF
36	Appendix – Publications



# Message from the **Chairman Liam Kelly**

For the past 15 years, the Gallipoli Medical Research Foundation (GMRF) has committed itself to fighting the impact of targeted serious illnesses. It has particularly dedicated itself to addressing illnesses that affect the lives of those who have served our great country in the military and to whom we all owe a genuine debt. GMRF has had, and continues to have, some great successes. It works for those suffering now and works for the benefit of future generations.

GMRF is carefully selective about what it seeks to achieve. It is adaptive and careful in the use of its resources and is true to its core values. We focus on what can be achieved with the resources which are generously entrusted to us by our many valued supporters. We set high standards and expect them to be met. Our staff are of the highest calibre, and we have a history of appointing directors who bring tremendous skills and experience to the Board of Directors. Each of our directors give of their time freely because they believe passionately in what the GMRF is about.

In the 2019/2020 Financial Year, a year that included the advent of the pandemic Covid-19, our team has taken some very significant steps forward. I consider it appropriate to celebrate and share this progress with you in this Annual Report.

Since the inception of the GMRF, being attuned to the needs of veterans, being innovative and collaborative have been at the heart of what we do. It is a testament to CEO Miriam Dwyer and the extremely dedicated and competent people around her that the Foundation has navigated the past months and maintained such a strong position in a time when charities have experienced difficulties across the sector.


It gives me immense pride to have the privilege to be the Chairman of a research institute that has not only weathered these challenges, but has actually grown measurably in size and scope during this most testing period. GMRF also maintains and continues to develop strong and important academic partnerships with the University of Queensland and other medical institutes in Australia and around the world.

I am very grateful to our dedicated and skilled Directors. I am delighted that GMRF has been able to attract three new very high-quality appointments to our board in the past Financial Year. The knowledge and experience brought by Professor John Horvath AO, Professor Scott Bell, and Dr Amanda Dines will contribute very positively to the future direction of this Foundation.

On behalf of the Board, I would like to thank sincerely the individuals, community groups and businesses



generously supporting GMRF's work. Our team are dedicated to repaying your generosity and shared commitment by tirelessly working towards success. Thank you for allowing us to continue our task and to allow us to benefit the community of Australia.

  
**Liam Kelly QC - Chairman**

***“GMRF has had, and continues to have, some great successes. It works for those suffering now and works for the benefit of future generations.”***

# Message from the **CEO Miriam Dwyer**



Medical research takes time, tenacity and a lot of hard work by a team of dedicated professionals. Sometimes the light at the end of the tunnel seems very far away. It is the support and encouragement of our research participants and generous donors that keep us focused on our vision of enhancing the health and wellbeing of the Australian community through the highest quality medical research.

This year we celebrated a special milestone — our 15<sup>th</sup> Anniversary. It has been with a great sense of pride that we have looked back over the past 15 years to take stock of the progress in innovative medical research and in the discovery of life-changing new treatments.

2020 has been a challenging year for everyone, but the GMRF team remain 100% committed to stay the course and continue our progress. I am incredibly proud of the team's dedication and the collaborations we have forged in the past 12 months.

Even through these challenging times, our research team continues to grow; with new staff and students coming on board to tackle more research questions. We are always coming back to the reason why we are here. It's about focusing on what matters to our veterans and their families, our patients, and our communities.

My heartfelt thanks to everyone who supported our research and initiatives. Everything we have achieved in the past 12 months would not be possible without this incredibly generous support. Your heartfelt belief in the research being undertaken at GMRF raises our spirits when progress is slow or when times are difficult. For

your belief in our work I want to say thank you!

I would also like to acknowledge the generous personal bequests from Jean Pockett, Joan Smith and Barbara Gay. These supporters have left a lasting legacy for good, and for the interests of beneficial medical discovery.

My sincere thanks to the GMRF Board of Directors and dedicated Patrons who give of their time voluntarily to guide and support our Foundation.

I also want to thank each and every member of the GMRF Team for their dedication, commitment and collaborative approach to research – you inspire me each and every day!

By working together, we can achieve real and meaningful change for our veterans, their families and our communities for generations to come.



**Miriam Dwyer - Chief Executive Officer**

*"We are always coming back to the reason why we are here. It's about focusing on what matters to our veterans and their families, our patients, and our communities."*

# Message from the **Director of Research Prof Darrell Crawford**

We have come a long way since we established the Foundation in 2005. We have grown, both in team size and the scope of our research, while constantly remaining focused on our vision. We exist to discover innovative solutions to the health problems affecting our veterans, their families, and our wider community.

The expansion of our research has continued its strong focus on veteran health research including veteran mental health – as well as liver disease, liver cancer and respiratory illnesses as these are common causes of morbidity and mortality in the veteran population.

We continue to grow our liver research capacity. Liver disease and liver cancer are among the greatest challenges of our time in health care and that drives our need to pursue research efforts in this field. To that end, we welcomed four new liver researchers to our team as part of a partnership with the University of Queensland's Diamantina Institute. The new projects, led by Dr Haolu Wang and Dr Tina Liang, are truly innovative and will impact on development and selection of anti-cancer therapies in the future.

It is a similar story for our Veteran Health Research.

In 2019/2020, this research team completed three projects, launched four new projects, and have a further three ongoing. Much of this research stems from the findings of the Foundation's world-first PTSD Initiative Study, in partnership with RSL Queensland, published in 2017. Driven by a desire to better understand the impact of military service on veterans and their families, the team is well-placed to deliver lasting solutions.


Our respiratory research has been buoyed by the promotion of Dr Rachel Thomson to Professor by The University of Queensland and her recent success in being awarded a highly competitive Queensland Advancing Clinical Research Fellowship. These successes testify to Professor Thomson's dedication and commitment to research. Her research in the field of respiratory diseases has major impacts for veterans and the community and Rachel leads a very strong team with outstanding global collaborations.

I strongly believe the next 12 months will likely be the most productive year to date for GMRF. The groundwork has been laid for our research to go from strength to strength. However, the outcomes we are producing could not be achieved without the generous support of

our donors and sponsors. We applaud your generosity, your commitment to research and your faith in our work. A most sincere thank you.



**Prof Darrell Crawford - Director of Research**



*"The outcomes we are producing could not be achieved without the generous support of our donors and sponsors. We applaud your generosity, your commitment to research and your faith in our work."*





# GMRF Profile & Strategy

## About us

Gallipoli Medical Research Foundation (GMRF) is a unique and successful hub for research and discovery. Founded in 2005 and based at Greenslopes Private Hospital, the former repatriation hospital in Brisbane, we continue the Hospital's proud tradition of supporting current and former service personnel through our pledge of *Remembrance Through Research*. We investigate areas of significant clinical need identified by a multi-disciplinary clinical leadership team. We engage with individuals, businesses, academic institutions and communities to grow our research and focus on translational research with immediate and meaningful impact.

## Our vision

Enhanced health of the Australian community through the highest quality research.

## Our mission

Lessen the impact of disease today while also searching for the cures of tomorrow by:

1. Working to alleviate the burden of the diseases directly impacting our veterans and their families.
2. Using a multi-disciplinary and collaborative approach to understand and address areas of significant clinical and social need.
3. Delivering high quality clinical trials of emerging therapies and interventions.
4. Facilitating and financially supporting a culture of research and innovation within Greenslopes Private Hospital.
5. Sharing our research findings for the greatest benefit of all.

## Strategic Intent

Driving the strategic direction for 2019-2023 are our core values of excellence, integrity, relevance and innovation. Our focused efforts will continue to deliver increased understanding around issues facing the veteran and military community, and those who love, support and rely on them.

We will continue our commitment to identify and deliver insights and therapeutic pathways that can change lives, improve treatments and cure disease within the general population. To enable this important work we will continue to strengthen our profile as a unique and successful research hub, demonstrate our impact and inspire financial support to ensure long-term sustainability.

**Maintain excellence in biomedical and clinical research**

**To be a voice that is trusted and respected by the military family and those organisations entrusted with their care**

**Translate awareness of GMRF into appropriate financial and other support for the work that we do**

**Share research outcomes and impact of our work to all Australians**

**Strengthen current academic partnerships and establish new affiliations to enhance the academic impact of GMRF**

# Highlights from 2019/2020

**4** new major projects  
expanding our scope of  
liver cancer research

**2** new studies launched into  
the comorbidities of PTSD

**47** clinical trials for new  
treatments in cancer, lung  
disease and other illnesses

*Published research findings on  
new treatments to target liver  
cancer cells*

*Validated a psychometric  
needs assessment measure for  
veterans adjusting to civilian life*

*Published trials data leading to  
registration of new melanoma  
treatment*

**17** publications improving  
understanding of  
respiratory illnesses

*Contribution of data from over  
200 patients to a national  
bronchiectasis registry*

**328** active participants in the  
GPH Cancer Wellness  
Program



# Veteran Health Research 2019/2020

## Veteran Health Initiative

**GMRF is committed to understanding the physical and psychological impact military service has on veterans and their families.**

With the partnership of RSL Queensland, our Veteran Health Initiative takes a holistic approach to research, aiming to develop evidence-based real-world solutions to enhance the quality of life for our veterans and their families.

**In 2019/2020, our Veteran Health Initiative:**

Completed three projects, launched four new projects, with a further three ongoing.



Projects encompassed three central research themes:

- PTSD and associated comorbidities
- Transition from military service and reintegration to civilian life
- Mental health and wellbeing programs for veterans and their families.



Expanded the team to 15 staff of clinical psychologists, researchers and project officers.

Published two papers, taking the total for the Veteran Health Initiative to 25 published manuscripts.

Presented at 12 major national and international conferences.



## PTSD and associated comorbidities

Our world-first PTSD Initiative findings, published in 2017, revealed the whole-body impact of posttraumatic stress disorder (PTSD). Gastrointestinal conditions were common among veterans with PTSD, while one in three may face problems due to multiple medications prescribed for mental health issues.

**To address these issues, we launched two new projects:**

**Investigating the link between PTSD and gut disorders**



- Launched an analysis of the rates of endoscopic investigations on veterans, with and without PTSD. The study aims to confirm the higher rate of endoscopic procedures for veterans with PTSD and expand on the limited clinical knowledge on the association between PTSD and gut symptoms. Data has been collected and statistical analysis is now underway.

**The quality use of medication**



- Launched the Quality Use of Medication Study to investigate the prevalence and impact of polypharmacy (the regular use of multiple medications) for treating veterans with PTSD. Data collection and analysis for this study is due to commence by the end of 2020. The study aims to identify risks associated with polypharmacy to inform clinical practice and prescribing guidelines.

**INFORMING NATIONAL POLICY** As a recognised expert in veteran health research, Associate Director Dr Madeline Romaniuk was invited to the Minister's Veteran Mental Health and Wellbeing Summit in 2019. Through this, Dr Romaniuk contributed to the development of the Department of Veterans' Affairs new 'Veteran Mental Health & Wellbeing Strategy 2020 – 2023'.



# Veteran Health Research 2019/2020

## Transition from military service & reintegration to civilian life

**Veterans may struggle with transition from service to civilian life. In a recent study commissioned by the Departments of Defence and Veterans' Affairs, it was estimated nearly half of Australian service personnel who had recently transitioned met 12-month criteria for a mental health condition.**

In partnership with RSL Queensland, we aim to improve the transition process and enhance quality of life for our veterans.

### Identifying the reintegration support needs of veterans



- Development, trial and analysis of adjustment and reintegration assessment measures. Led by Associate Director of Veteran Health, Dr Madeline Romaniuk, the project team have submitted the manuscript on the study of these measures. The first of their kind available globally, these measures will enable timely detection and assessment of reintegration difficulties. They will also significantly enhance clinicians' understanding of the relationship between transition and reintegration difficulties and mental health, which will lead to more targeted intervention.



- Findings are being used to develop a self-directed education program for veterans which addresses identified needs. The program will be piloted by the end of 2020.



### Assessing readiness for civilian life



- An extension of the Veteran Reintegration Study, the Civilian Readiness Study aims to improve transition for Australian service veterans by focusing on developing a method to determine 'readiness' for civilian life prior to discharge.
- Recruitment activities commenced in 2019, with over 200 current service personnel in the process of transition completing the first in a series of three surveys.
- The project received endorsement and support from ADF Joint Health Command and Major General Natasha Fox (Head of People Capability, Defence People Group).
- The measure produced by this research will enable the timely detection and assessment of an individual's needs prior to transition. It will also inform the development of education programs to 'upskill' current serving ADF members based on their needs and better equip them for the transition process.



*"I completely oversimplified the transition process. I told myself, 'if you can survive in the Army, you can survive in civilian life'. But civilian life is a totally different landscape – both physically and mentally. No one explained that to me or gave me tools to deal with it." Tim Thomas, GMRF Veteran Ambassador*

# Veteran Health Research 2019/2020

## Mental health and wellbeing programs for veterans and families

In 2019/2020, the Veteran Health Initiative conducted a number of research projects aimed at addressing mental health issues and improving overall wellbeing for veterans and their families.

### Improving sleep quality for veterans with PTSD



- Continued the Veteran Sleep Therapy Study investigating the use of both evidence-based and novel psychological interventions to improve sleep quality. 91% of veterans with PTSD suffer from sleep disturbances.




- Completed the first round of group therapy sessions in December 2019, with groups to continue throughout 2020.
- A manuscript on the methodology of the study is being prepared for submission. The research aims to use findings from the study to inform treatment to improve sleep and overall quality of life for veterans with PTSD.

### Investigating mental health programs for veterans and their families



- Completion of two major projects investigating mental health programs for veterans and families. The Mental Health First Aid and Compassionate Mind Training studies contributed to further understanding on these interventions and recommendations for improving clinical practice.




**The impact of military service can extend beyond the individual and affect the whole family.**

### Enhancing support for families with a veteran



- Conducted research to improve health and wellbeing outcomes for veteran families. The project developed recommendations for a model of care to guide service delivery for veteran families with complex, multi-agency needs. The recommendations will form the basis for a pilot implementation of the proposed model of care.

# Liver Research 2019/2020



**"The liver disease epidemic continues to skyrocket. We need to grow our research capabilities to deliver better treatment for those who have liver problems. We can't achieve that goal without the support of our generous donors." Professor Darrell Crawford, GMRF Director of Research**

**The growing Liver Research Unit at GMRF is investigating new ways to predict, prevent and treat illnesses of the liver, as well as increasing the number of donor livers suitable for transplant.**

**In 2019/2020, our Liver Research Unit:**



- Partnered with University of Queensland Diamantina Institute and introduced Dr Tina Liang and Dr Haolu Wang as Liver Cancer Research Leads. The expanded Liver Research Unit now includes 4 research leads, 2 research fellows and 4 PhD students working across projects in liver disease, liver cancer and bile duct disorders.



- Published 21 journal articles and abstracts.
- Presented at five national and international conferences.
- Expanded the scope of research with two new projects in bile duct disorders – an area of liver injury that is currently poorly studied.



- Facilitated new and strengthened existing collaborations in liver cancer research by hosting the third annual Experimental Liver Cancer Forum.

**KEY PUBLICATION: TNF- $\alpha$ -mediated epithelial-to-mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma. Published in 'Molecular Medicine', 2020.**

There are very few treatments for liver cancer and the mortality rate is increasing. Even with treatment, recurrence of cancer is high and cancer cells evade detection. We urgently need to find novel therapies. This publication examines ways that cancer cells change their behaviour to escape detection and proposes new treatments to target cancer cells that could be used along with current treatments to improve patient outcomes.



# Liver Research 2019/2020

## Liver Disease

**Liver disease is a silent epidemic that affects around six million Australians.**

**Contributing factors can include excess iron, fat and/or alcohol.**

Fatty liver disease is challenging to treat. There are often no obvious symptoms until it becomes a serious problem. Currently, 40% of livers are rejected as donor organs, with excess fat greatly increasing the risk of failure post-transplant.

**In 2019/2020, we progressed two liver disease research projects:**

### Combating the role of iron in liver injury




- Continued ongoing research into understanding how co-toxic liver injury (caused by excess iron and alcohol) progresses and how it can be counteracted. PhD Student, Afolabi Akanbi, is now testing the theory that restoring iron balance using hepcidin can eliminate liver injury.
- This would be a new therapeutic approach and has strong translational potential – taking it from bench to bedside.

### Improving liver transplant outcomes



- Progressed a study exploring how more fatty livers could become viable for liver transplantation. PhD Student, Raji Baidya, identified key cell death pathways in injured livers and therapeutic agents which could prevent cell death and reduce the risk of transplant failure.



## Bile Duct Disorders

There are very few treatments for bile duct disorders and cholangiocarcinoma (cancer of the bile duct) and publications on these disorders are limited.

**In 2019/2020, we launched two new research projects into bile duct disorders:**

### Improving treatment efficacy of stem cell-based therapy for bile duct disorders



- Launched a new study investigating methods to improve the effectiveness of current treatments in treating bile duct disorders, including cholangiocarcinoma.

### Identifying new drug targets for bile duct disorders



- Launched study identifying new treatment approaches to bile duct cancer. The study is exploring the significant differences between how bile duct and liver cell cancers behave. The study aims to inform treatment selection in the future, combining established and emerging treatments.

# Liver Cancer Research 2019/2020

**One in four Australians has or will develop fatty liver disease. If left untreated, it can lead to liver cancer — the fastest increasing cause of cancer death in Australia. For some people, a liver transplant is the only option.**

**In 2019/2020, we focused on five key liver cancer research projects:**

## **Developing a liver cancer nanovaccine**



- Launched a project to develop a therapeutic vaccine for liver cancer to help immune cells recognise and kill cancer cells. Led by Dr Haolu Wang, the project is nearing completion of the first phase with early findings planned for publication in 2020. The aim of the treatment is not only to kill cancer cells, but to prevent the tumour coming back long-term.

## **Inhibiting tumour self-seeding and cancer recurrence**



- Commenced an investigation into a potential drug treatment that would prevent detached liver cancer cells from returning to the tumour.
- Project lead, Dr Tina Liang will begin validation of the treatment model later in 2020.

## **Altering the tumour microenvironment**



- Commenced a research project to investigate how the liver microenvironment contributes to tumour progression. The study aims to improve sensitivity of cancer cells to chemotherapeutic agents.



Joining the team in 2019, **Dr Liang** is leading two major liver cancer projects. In 2019/2020, Dr Liang received the Promoting Women Fellowship and the NanoString Fibrosis Grant Award — one of just four recipients globally.



**Dr Wang** joined the unit as a research lead in 2019. He is leading two major liver cancer projects. In 2020, Dr Wang was successful for a UQ Early Career Researcher Grant through the University of Queensland Diamantina Institute.

## **Improving screening measures for liver disease and liver cancer**



- Commenced research into the development of a saliva and blood-based method to detect liver disease and liver cancers at an early stage. PhD student, Lucas Trevisan Franca de Lima, has conducted a pilot study to compare identifiable biomarkers in patients with liver cirrhosis.

## **Identifying druggable targets in liver cancer**



- Continued ongoing research targeting cancer stem cells. PhD Student, Ritu Strestha, is conducting research to determine what makes cancer stem cells resistant to current therapies so that they can be re-sensitised to drug treatment. Her findings will identify novel therapeutic approaches in liver cancer that aim to improve treatment response rates and patient survival.



# Respiratory Research Activities 2019/2020

**Non-tuberculous mycobacterial (NTM) infections and bronchiectasis are closely connected respiratory illnesses that are rising in prevalence.**

We are working to better address the significant gap in understanding of these illnesses – the incidence, how they are acquired, how we may be able to diagnose and control them through prevention and better treatment options for those affected.

## Bronchiectasis



- Contributed data for nearly 200 patients to the first national bronchiectasis registry. The unit is part of a national collaborative project with a network of 11 researchers and clinical experts contributing comprehensive data to the Australian Bronchiectasis Registry.
- The learnings from this project will lead to improved health outcomes through better education, treatment and support.

## Non-tuberculous mycobacterial infections (NTM)



- Continued ongoing research into understanding the environmental and transmission aspects of NTM in order to develop better ways of controlling the spread of infection and reducing the risk of contracting an infection. Explored aspects of patients' immune system that might lead them to getting these infections, in an effort to offer better treatments.



"This is an exciting time of growth for our unit, with increasing awareness of the significance of bronchiectasis and NTM lung disease in the community. Our high-calibre team are excited to be tackling the major issues facing patients with these conditions."

**Professor Rachel Thomson,**  
**Head of the GMRF Respiratory Research Unit**



- Contributed to ongoing epidemiology study and national treatment trials to provide high quality evidence to guide clinicians towards better treatment protocols for NTM and bronchiectasis, minimise toxicity and treatment burden and maximise patient health outcomes. This includes NTM in cystic fibrosis and treatment of non-CF bronchiectasis.



- Unit lead Prof Rachel Thomson is a Principal Investigator of the ground-breaking FORMAT trial to assess combination therapies for *M. abscessus* infection at multiple international sites.



**KEY PUBLICATION: Management of Australian adults with bronchiectasis in tertiary care: evidence-based or access driven? Published in 'Lung', 2019.**

Using data from the Australian Bronchiectasis Registry, the publication revealed discrepancies between guideline recommendations and real-world treatment of bronchiectasis. The findings highlight the need for a review of treatment access and will inform ongoing education to promote evidence-based care for people living with bronchiectasis.

# Other Research Activities 2019/2020

## Affiliated Research

**The rate of oesophageal cancer has risen seven fold in the last three decades, causing over 1,500 deaths in Australia in 2018 alone.**

Affiliated researcher and clinician, Associate Professor Luke Hourigan, is conducting research into Barrett's Oesophagus (BO), a precursor to oesophageal adenocarcinoma (OAC).

**In 2019/2020, Assoc Prof Hourigan's research focused on:**



- Identifying more effective treatment options for oesophageal adenocarcinoma
- Launched the Australian Barrett's Cohort with Dysplasia and Early Cancer Study (ABCDE Cancer Study) in late 2019. The focus of this study is to contribute to and analyse a national database to identify at-risk patients for earlier detection and identify optimal treatment options for OAC.



- The first publication on this study was recently published in industry-leading journal 'Endoscopy'. The endoscopic management of BO published in this journal represents a paradigm shift for the treatment of this disease, which previously required surgical oesophagectomy.
- This endoscopic technique, in combination with superficial thermal therapy, is now used in clinical practice and is producing high rates of cure while enhancing quality of life for patients.



Affiliated Researcher, Assoc Prof Luke Hourigan

*"The outcomes of this study could be life-changing for thousands of Australians. If we can recognise patient risk factors that lead to progression of cancer, our surveillance strategies and treatment options could potentially be more targeted and effective."* Assoc Prof Luke Hourigan

# Clinical Trials Unit 2019/2020

**Our Clinical Trials Unit (CTU) works with leading clinicians to provide patients early access to ground-breaking treatments — a vital step in the drug development pathway from research to standard of care for future patients.**

Over the last 12 months, the CTU has worked with 15 clinical investigators across 47 active trials. We have commenced eight new trials with a further five in start-up, including 'first in man' and 'proof of concept' studies.

The CTU contributed to further clinical trials through the Ramsay Health Care Clinical Trials Network. One of 14 centres, the CTU assisted in site start-up processes, enabling trials to start sooner and improving patient access to new treatments, particularly in regional areas.

## Oncology



- Expansion of oncology trials in lung cancer and cutaneous squamous cell carcinoma (a type of skin cancer).
- Launched earlier disease stage clinical trials in melanoma and prostate cancer aimed at preventing disease progression.
- Publication of five clinical trial studies in high-impact journals involving GMRF affiliated investigators in melanoma and squamous cell carcinoma.
- Produced trial outcome data which contributed to the registration of earlier Stage III Melanoma Immunotherapy treatment on the Pharmaceutical Benefits Scheme, giving the community affordable access to this ground-breaking new treatment.



"The whole team were absolutely outstanding. They treat you like family. It was an exceptional experience and such a great result for me."  
**Bruce, completed GMRF melanoma trial in 2020.**

## Liver Disease



- Continued ongoing clinical trials in non-alcoholic fatty liver disease and haemochromatosis. These predominantly Phase III trials have received encouraging interim results.

## Respiratory Illness



- Expanded trials in non-cystic fibrosis bronchiectasis in isolation and with other infectious agents such as Non Tuberculous Mycobacterium (NTM). The trials data of a Phase II study has translated to the expansion into Phase III Trials — the phase before a new treatment can be registered and made available to the community.

**15**

clinical investigators

**47**

active trials

**8**

new trials



# GMRF Innovation Grants 2019/2020

**The GMRF Innovations Grants Programs empowers health professionals at Greenslopes Private Hospital to conduct their own research projects.**

Through GMRF grant funding and the support of Thynne + Macartney, hospital staff have improved clinical outcomes by investigating new processes, education and training methods and the trial of innovative software and equipment.

**In 2019, a Thynne + Macartney Discovery Grant funded:**

**Education to improve Junior Medical Officers (JMOs) communication skills with patients**



- Medical Education Coordinator, Dr Tracey Papinczak, conducted a project to improve communication skills of JMOs. Dr Papinczak developed six interactive online modules focused on vulnerable groups and those with specific needs. The modules were trialled by 28 interns at Greenslopes Private Hospital.
- Positive feedback was received and statistically significant increases in understanding were shown in:
  - Awareness of Aboriginal and Torres Strait Islander culture and communication.
  - Skills in delivering culturally safe care to Aboriginal and Torres Strait Islander patients.
  - Confidence in managing challenging communication with Aboriginal and Torres Strait Islander patients.

***The GMRF Innovation Grants Program is made possible by Thynne + Macartney Lawyers, Greenslopes Private Hospital, and generous GMRF donors.***



**Thynne  
Macartney  
Lawyers**

**Greenslopes  
Private Hospital**  
Part of Ramsay Health Care

# GMRF PhD Scholarship Program 2019/2020



**Afolabi Akanbi:**  
Fighting liver disease  
by understanding iron  
overload



**Afolabi completed the first year of his PhD project in understanding and addressing the role of iron in fatty liver disease progression.**

## RESEARCH FOCUS

Afolabi's research project will help to determine the role iron plays in progression of the two most common liver disease in western world — alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD). A protein called hepcidin is known to regulate total iron body stores and this project will help us to clarify if hepcidin can restore iron homeostasis in liver disease state and thus reduce the effect of excess iron in liver injury. This would be a novel therapeutic approach for these diseases and thus these studies have strong translational potential.

Afolabi's project receives generous funding from the John & Wendy Thorsen Foundation.

**Next Steps:** *Afolabi will conduct analysis to examine the role iron, alcohol and hepcidin play in altering fat cells. These experiments will help determine the therapeutic potential of hepcidin.*



**Raji Baidya:**  
Preventing cell death  
pathways in transplant  
livers

**Raji is in the final year of her PhD project. She submitted her final progress report in July 2020 and presented at Australian Gastroenterology Week 2019.**

## RESEARCH FOCUS


Raji is studying how more fatty livers could become viable for liver transplantation. As part of this, she is exploring a form of cell death called necroptosis, which is particularly important during liver transplant when there is an interruption to the blood supply during surgery. Raji has identified key cell death pathways in injured livers and therapeutic agents which could prevent cell death and reduce the risk of transplant failure.

Raji's research will lead to more fatty livers successfully used in liver transplantation and reduce the number of deaths on the liver transplant waiting list.

**Next Steps:** *Raji will continue work on her thesis review with planned submission in January 2021. She is also preparing several manuscripts for publication.*



# GMRF PhD Scholarship Program 2019/2020



**Lucas Trevisan  
Franca de Lima:**

Using saliva to detect liver injury



**Lucas is in the first year of his PhD project investigating a novel approach to earlier detection of liver disease and liver cancer.**

## RESEARCH FOCUS

Lucas's research project is investigating the use of saliva as a diagnostic tool to detect liver disease or liver cancer. He has completed a pilot study looking at the blood and saliva biomarkers of patients with liver fibrosis and healthy volunteers. Biomarkers are signatures that can be objectively measured so they can be used as an indicator of a normal biological process or a disease. The early findings have been very promising, with Lucas identifying the same biomarkers in the blood and saliva. Lucas currently has his first paper under review for publication.

Lucas's project receives generous funding from the John & Wendy Thorsen Foundation.

**Next Steps:** *Lucas will expand the study to a larger patient cohort. He aims to evaluate how salivary biomarkers reflect liver biochemical parameters as well as the degree of scarring in the liver.*



**Ritu Strestha:**

Identifying new drug targets for better liver cancer treatments

**Ritu is in the final year of her PhD Project. She is preparing her thesis for submission and has several published manuscripts in peer-reviewed journals.**

## RESEARCH FOCUS

Ritu is in the final year of her three year research project. She is aiming to determine what makes cancer stem cells resistant to current therapies so that they can be re-sensitised to drug treatment. Her findings will identify novel therapeutic approaches in liver cancer that aim to improve treatment response rates and patient survival.

In the 2019/2020 Financial Year, Ritu had two first author publications and one second author publication in a peer review journal, with another manuscript currently under review. Ritu was a finalist of the GESA Young Investigator Award 2019 and presented at five national and international conferences.

**Next Steps:** *Ritu will conduct final lab experiments, data analysis complete her thesis review. Ritu aims to submit her final thesis in January 2021.*

# GMRF PhD Scholarship Program 2019/2020

## SLAWOMIR ANDRZEJEWSKI OPHTHALMOLOGY RESEARCH

Slawomir Andrezejewski is in the fourth year of his PhD investigating aspects of therapeutic targeting in retinal disease. The aim of his research project is to develop gene therapy to treat various blinding conditions such as diabetic retinopathy.

In the 2019/2020 Financial Year, Slawomir achieved a number of important discoveries in gene therapy. In order to improve future gene therapy clinical trials success, He conducted experiments designed to obtain new preclinical data allowing an increased gene transfer in human retina and subretinal tissue.

In addition, Slawomir completed research to target cancer which affects the human eye. Using AAV viruses containing therapeutic genes, he tested whether a gene therapy approach might also be used to help those who are affected by this disease. Detailed and encouraging results have been produced so far, which could be used as an alternative approach to currently available treatment options.

He completed the final draft of his third, first author original research paper, and presented at the ASGCT 23rd Annual Meeting, Virtual Conference.

*Slawomir's PhD scholarship is funded through the generous support of the John & Wendy Thorsen Foundation*

## WOLE AKOSILE VETERAN MENTAL HEALTH RESEARCH

Dr Wole Akosile, psychiatrist and QUT PhD candidate, is using the data from the PTSD Initiative Vietnam Veteran Study to undertake his PhD entitled *Molecular mechanisms and pathways in the development of cardiovascular disease in individuals with PTSD*.

Dr Akosile's thesis provides strong evidence of the link between PTSD and coronary artery disease. It demonstrates the link between stress and chronic medical and psychological disorders. This research reveals that chronic medical disorders and psychological disorders may be linked to chronic inflammation. Strategies to prevent and treat these disorders may involve activities that reduce chronic inflammation, including good diet, good sleep, exercise and good stress management strategies.

The potential impact of this research project includes the possibility of new pharmacological approaches to the treatment of psychological illnesses by targeting chronic inflammation and this research makes a case for personalised medicine and the role of genetic testing in the treatment of chronic disorders.

Dr Akosile submitted his thesis for external examination in June 2020.

# GPH Cancer Wellness Program

**The Greenslopes Private Hospital Cancer Wellness Program continues to grow, providing information and support to patients and their carers throughout the cancer journey.**

Now in its fourth year, the program forms a valuable part of the hospital's holistic approach to cancer care and complements clinical and allied health services.

## **In 2019/2020, the GPH Cancer Wellness Program:**

- Delivered monthly seminars covering topics on stress management, mindfulness, exercise, finance and legal services, and survivorship.
- Facilitated a supportive community with regular activities such as yoga and craft.
- Adapted in response to the coronavirus pandemic to continue delivering information and support online. Weekly newsletters were sent to participants and online resources such as exercise videos were offered through GMRF's website.
- Conducted the Men's Cancer Wellness Pilot Program. The six week program provided tailored activity sessions and practical ways for participants to improve mental and physical health and make positive changes to their daily lives.

## **What's Next?**

As patient safety is the highest priority, the program will continue to be operated in an online capacity. Regular online seminars are planned for the 2020/2021 Financial Year.

The Cancer Wellness Program is made possible by generous GMRF donors. To find out more or to support the program, visit [www.gallipoliresearch.com.au/cancer-wellness](http://www.gallipoliresearch.com.au/cancer-wellness)

**600**

Patients reached since the program launched in 2017

**328**

Active participants in the program in 2019/2020



**"The Cancer Wellness Program has been such a wonderful support — you've always got someone there to help you. It's given me the knowledge and resources I need, from a source I trust, to take charge of my cancer journey." Bianca, Cancer Wellness Participant**

# GMRF Board of Directors

## Chairman

### Mr Liam Kelly

**BA (Hons) LLB (Hons) (UQ)**

Liam Kelly graduated from the University of Queensland in 1988 with honours in English literature and in law. He was awarded the university medal for law. He was also awarded the Rhodes Scholarship for Queensland in 1989 and attended Magdalen College at Oxford University from where he graduated in 1991 with a Bachelor of Civil Law. He commenced private practice as a barrister in Brisbane in 1992 and continues to practise at the bar as a Queen's Counsel. His field of work is commercial litigation.



## Deputy Chairperson

### Ms Chris Went

**CEO of Greenslopes Private Hospital**

Chris Went was appointed to the position of CEO at Greenslopes Private Hospital on 11 December 2017. Ms Went was previously CEO at St Andrew's Ipswich Private Hospital (also a member of Ramsay Health Care). Having completed her nursing training in 1992, Chris also has post graduate qualifications in the clinical specialties of cardiology and emergency as well as business administration.

Chris has represented the private sector on the Queensland Clinical Senate for the past six years, was a member of the Department of Health Patient Safety Board for three years and has represented the Australian Private Hospitals Association on the Queensland Clinical Education and Training Council.





# GMRF Board of Directors

## Company Secretary

### **Ms Carmel Monaghan**

**B.BusComm, MBA**

Carmel Monaghan was appointed Chief Executive Officer (CEO) of Ramsay Health Care's (Ramsay) Australian operations on 1 October 2020. Ms Monaghan has worked across hospital, corporate and global positions in Ramsay for over two decades. Prior to her appointment as CEO of Australia, Ms Monaghan was the Group Chief of Staff of Ramsay's global operations gaining extensive experience and a comprehensive understanding of health care operations and strategy both in Australia and overseas.

Ms Monaghan has also served as the Group Head of Marketing and Public Affairs directing the Company's marketing, brand and communications strategy through a time of several major mergers and acquisitions both within Australia and overseas as it grew from 12 facilities to over 500, becoming one of the leading private health care operators in the world.



Ms Carmel Monaghan

### **Professor Scott Bell**

**MBBS, FRACP, MD**

Professor Scott Bell is the Chief Executive of the Translational Research Institute and a Senior Physician of the Adult Cystic Fibrosis Centre at the Prince Charles Hospital where he has worked since 1996 in Brisbane. He leads the Lung Bacteria Laboratory at UQ's Children's Health Research Centre.

Prof Bell has over 250 peer reviewed publications and has received more than \$22 million in grant support in the past 10 years. His research interests include the CF microbiology, acquisition pathways for human infection and has a long history of supporting multi-disciplinary research. He has been principal investigator on numerous pivotal cystic fibrosis transmembrane conductance regulator (CFTR) modulator trials and is global principal investigator on a novel approach to combination



Professor Scott Bell



# GMRF Board of Directors

## Dr Amanda Dines

**MBBS, MPH, FRACGP, FRACMA**

Dr Amanda Dines was appointed as the Deputy Executive Director Medical Services of Metro North Hospital and Health Service in May 2019. She served as the Director of General Health Reserves in the Royal Australian Air Force from 2012 to 2015. Since 2014, she has also served as the Honorary Aide de Camp to the Governor General of Australia. Dr Dines has been an Adjunct Associate Professor at the University of Queensland Medical School since 2018.



Dr Amanda Dines

## Dr Michael Harrison

**MBBS(1st Class Honours). FRCPA (General Pathology)**

Dr Michael Harrison is the Chief Executive Officer/Managing Partner of Sullivan Nicolaides Pathology and is a Consultant Pathologist at the main Taringa Laboratory.

Dr Harrison graduated from the University of Queensland in 1977 with an MBBS (1st Class Honours) and in 1984 was awarded FRCPA (General Pathology). Dr Harrison is the President of Royal College of Pathologists of Australasia and Chairman of the Quality Use of Pathology Committee. He has presented at many national and international meetings on the topics of Quality, Laboratory Management and eHealth.



Dr Michael Harrison

# GMRF Board of Directors

## Professor John Horvarth

**M.B, B.S, E.C.F.M.G., M.R.A.C.P., F.R.A.C.P., F.R.A.C.P.(Hon), F.A.A.H.M.S.**

Professor John Horvath AO was appointed as Strategic Medical Advisor for Ramsay Health Care in 2016.

Professor Horvath served as Australia's Chief Medical Officer between 2003 and 2009 and has served as Chair of the Health Committee on the National Health and Medical Research Council (NHMRC). He has been a Board member of the Garvan Institute, Health Workforce Australia and Crown Resorts Ltd, and most recently served as Principal Medical Consultant to the Department of Health and Ageing from 2009 until recently.


Before joining the Department of Health, Professor Horvath's career included 30 years in clinical practice at the Royal Prince Alfred where he established a number of clinical services and as Director of the Renal and Transplant Services. He has been active in teaching and research; policy development and implementation of national strategies on behalf of governments. He has represented Australia's interest with the World Health Organisation and was Deputy Chair of the WHO's international cancer research institute based in Lyon, France. He was awarded an Officer in the Order of Australia in 2001.



## Mr Tom Ryan

**B Pharm, FACP, FAICD**

Mr Tom Ryan formerly a Director and Chairman of Australian Pharmaceutical Healthcare Systems (APHS). Mr Ryan was a founding partner of the APHS Group. The APHS group provides pharmacy services within private hospitals, as well as providing oncology services to a variety of public and private hospitals and also providing an extensive service to aged care facilities for both prescription supply and clinical consultancies, and community pharmacy services. Mr Ryan owned and operated the pharmacy service at Greenslopes Private Hospital from 1995 until 2010.



# GMRF Board of Directors

## Professor Gerald Holtmann

**MD, PhD, MBA, FRACP, FRCP**

Professor Gerald Holtmann is a Clinical Academic with substantial leadership experience in the clinical and academic setting. He is Director of the Department Gastroenterology and Hepatology at the Princess Alexandra Hospital in Brisbane, and serves on the Board of Directors of the West Moreton Hospital and Health Service and is the Associate Dean Clinical at the University of Queensland. His research in the field of Neurogastroenterology has been published in more than 350 articles and book chapters in leading journals including the NEJM, Lancet and Gastroenterology. Besides his clinical and academic activities, he completed a Master in Business Administration (MBA) at the University of South Australia.

Prof Holtmann retired from the GMRF Board of Directors in April 2020.



## Professor Ross Young

**BSc(Hons), MSc, Dip Clin Psyc, PhD, MAPS**

Professor Ross Young was appointed Executive Dean, Faculty of Health QUT in January 2013 following seven years as Executive Director, Institute of Health and Biomedical Innovation (IHBI), QUT. Professor Young is a Clinical Psychologist and his research interests lie in the integration of psychological and biological risk factors in mental illness. His research includes work in substance misuse, schizophrenia, anxiety disorders, mood disorders and more broadly in behavioural medicine. This includes work in pharmacogenomics and the development of personalised medicine via the use of gene chips. Professor Young has over 210 published book chapters and papers in genetic, medical, psychiatric and psychological journals.

Prof Young resigned from the GMRF Board of Directors in February 2020.



# GMRF Board of Directors

## Mr Karl Morris

**BCom, FAICD, MSAFAA, FFSIA**

Karl Morris is Executive Chairman of Ord Minnett Limited with a career spanning over 30 years in financial services and wealth management. He is a Commerce graduate of Griffith University and holds diplomas from the Stockbrokers and Financial Advisers Association of Australia, Institute of Company Directors and FINSIA. Mr Morris is Chairman and a Master Member of the Stockbrokers and Financial Advisers Association of Australia, Chairman of QSuper, Director of the Royal Automobile Club of Queensland (RACQ), Board Member of JP Morgan Australia Advisory Council, Board Member of the Financial Sector Advisory Council, Board Member of Archdiocese of Brisbane Catholic Foundation, Chair of Mary MacKillop Brisbane Catholic School Access Fund, Chair of Griffith University Foundation Board, Governor of the University of Notre Dame Australia and Patron of Bravehearts.

Mr Morris resigned from the GMRF Board of Directors in December 2019.



# GMRF Patrons

## Patron — Dame Quentin Bryce

AD CVO

Ms Quentin Bryce has enjoyed a rich and distinguished career as an academic, lawyer, community and human rights advocate, senior public officer, university college principal, and vice-regal representative in Queensland and for Australia.

Her contribution to advancing human rights and equality, the rights of women and children, and the welfare of the family was recognised in her appointment as an Officer of the Order of Australia in 1988 and a Companion of the Order of Australia in 2003. Also in 2003, she was invested as a Dame of Grace of the Most Venerable Order of the Hospital of St John of Jerusalem. On 5 September 2008, Ms Quentin Bryce was sworn in as Australia's twenty-fifth Governor-General. Her term concluded in March 2014 and Prime Minister Tony Abbott announced on 25 March 2014 that Ms Bryce had become a Dame in the Order of Australia.



Dame Quentin Bryce

## Patron — Professor John Pearn

AO RDF MBBS (Hons I), MD (Qld), PhD (Lond), DSc, MPhil, DCH, FRACP, FRCP, FRCPS (Glas), FRACMA, FCollTropMed (Australas), FCollTropMed (USA), FAMA, FADI, FAIM, FLS

Major General John Pearn has served as one of Australia's most senior doctor-soldiers. As Professor Pearn, he is a Senior Paediatrician at the Queensland Children's Hospital in Brisbane; where, at its predecessor the Royal Children's Hospital, he has been a full-time staff clinician since 1968. His major clinical, research and teaching interests in paediatrics and internal medicine have included medical genetics, clinical toxicology, bioethics and accident prevention. Major General John Pearn also served in a second career in the Australian Defence Force, rising progressively through various senior command and executive positions in the Defence Health Service. In 1998 he was appointed Surgeon General to the Australian Defence Force. Professor Pearn retired from the GMRF Board on 14th November 2018.



Professor John Pearn



# GMRF Ambassadors

## Veteran Ambassador — Tim Thomas

Tim Thomas is an ex-special forces Commando with deployments to Afghanistan and East Timor. He is a passionate advocate of better understanding and support for ex service personnel as they transition from service to civilian life. Tim joined the GMRF Team as a Veteran Ambassador to help promote GMRF's research in veteran mental health and reintegration.



## GP Ambassador — Dr Phil Parker

Dr Parker works as a general practitioner at Newstead in inner Brisbane. He enlisted as an Army soldier in 1988 and has served in both full and part time roles over 27 years. In 2012, he deployed to Afghanistan as the Senior Medical Officer in the province of Uruzgan. In this role he coordinated coalition forces medical care and provided mentoring to senior Afghan military and police health staff.

Dr Parker is also an experienced and qualified educator, a role that has supported his affiliation with the GMRF. As the Foundation's GP Ambassador, he provides advice about PTSD management within primary health care and continues to educate fellow GPs about the condition. As a GP, Dr Parker remains committed to the care and support of veterans and their families.



## Media Ambassador — Pat Welsh

7 News sports editor, reporter and presenter Pat Welsh is one of Australia's leading sports journalists and commentators. Pat is best known for his all-round sporting knowledge and presenting prowess. His extensive experience includes nine Olympic Games, rugby league, horse racing, cricket and three decades of golfing commentaries. Pat was a Founding Board Director for the Gallipoli Medical Research Foundation. He's continued his unwavering commitment to the Foundation as an Ambassador, generously donating his time and talents to GMRF events such as the Supporter High Tea and the Research Awards Night.



# GMRF Committees

## Executive Committee

**The role of the GMRF Executive Committee is to implement the strategic direction of the Board of Directors and to oversee the day to day management of the Foundation in line with our vision, mission and values.**

2019/2020 Members

- Mr Liam Kelly, GMRF Chairman
- Ms Carmel Monaghan, GMRF Company Secretary
- Ms Chris Went, GPH Chief Executive Officer
- Ms Miriam Dwyer, GMRF Chief Executive Officer
- Ms Jane O'Brien, GMRF Chief Operating Officer
- Professor Darrell Crawford, GMRF Director of Research
- Dr Suzanne Elliott, GMRF Associate Director of Clinical Trials
- Dr Madeline Romaniuk, GMRF Associate Director of Mental Health Research
- Ms Emma Bryant, GMRF Director of Development

## Research Advisory Committee

**The Research Advisory Committee (RAC) has been established by the Gallipoli Medical Research Foundation (GMRF) Board of Directors to provide independent expert advice to the Board to ensure the highest quality research is considered, supported and delivered by the Foundation.**

2019/2020 Members

- Dr Amanda Dines (Chair)
- Prof Scott Bell
- Prof John Horvath
- Dr Andrew Khoo
- Dr Ian Gardner
- Dr Richard Skoien
- Dr Michael Harrison (resigned 12/03/2020)
- Prof Gerald Holtmann (resigned 20/04/2020)
- Prof Ross Young (resigned 18/02/2020)

# Acknowledgment

**Our heartfelt thanks to the 1,010 donors who gave generously in 2019/2020 to fund our research and initiatives.**

Special mention to the John & Wendy Thorsen Foundation, Maria & Angelo Doukas, Logan Family Foundation, Civic Solutions, Curavis Fund, Ramsay Hospital Research Foundation and NFIA Patron's Walk for

Charity. Combined, these supporters donated \$562,233.

GMRF was honoured to receive generous bequests from Jean Pockett, Joan Smith and Barbara Gay. These supporters have left a lasting legacy of discovery.

We are proud to partner with leading organisations. These Corporate Discovery Partners made significant financial and in-kind contributions to our work.



## Corporate

### **Emeritus Plus (\$5 million +)**

Greenslopes Private Hospital & Ramsay Health Care

RSL Queensland

### **Emeritus (\$1 million +)**

Faculty of Medicine, The University of Queensland

### **Mastery (\$500,000 +)**

Sullivan Nicolaides Pathology

### **Visionary (\$250,000 +)**

Medibank

Medinet

### **Innovator (\$50,000 +)**

APHS

Baxter Healthcare

Calleija Jewellers

Channel 7 News

Device Technologies Australia

Flight Centre Limited

Johnson & Johnson Medical Pty Ltd

Medtronic Australasia Pty Ltd

Olympus Australia Pty Ltd

Phillips Medical Systems

QML Pathology

Queensland University of Technology,

Institute of Health and Biomedical

Innovation (IHBI)

Queensland X-Ray

Roche Products Pty Ltd

Spotless Group Limited

Stryker Australia

Thynne + Macartney Lawyers

## Foundations, Trusts & Estates

### **Emeritus (\$1 million +)**

John & Wendy Thorsen Foundation

### **Mastery (\$500,000 +)**

Ramsay Hospital Research Foundation

### **Visionary (\$250,000 +)**

Paul Ramsay Foundation

### **Innovator**

Cory Charitable Foundation

The Curavis Fund

Goldman Sachs JBWere Foundation

The Honda Foundation

James N Kirby Foundation

State Trustees Australia Foundation

## Estates

Estate of Christina Ann Alexander

Estate of Mr Victor John Bahr

Estate of Mrs Norma Jean Bracken

Estate of Mr Robert Chigwidden

Estate of Mr Jeremiah Coffey

Estate of Mrs Marjorie H Eastman

Estate of Barbara Gay

Estate of Mrs Josie Clare Grinsell

The Family of Dick and Elsie Hagerty

Estate of Mrs Mary Lamond Hinkley

Estate of Elizabeth Hughes

Estate of Mr Mark Kelly

Estate of Jean Linz

Estate of Eugenie J MacLennan

Mr G.D (Doug) Murray

# Acknowledgment

Estate of Shirelle Nahow

Estate of Mrs Jean Pocket

Estate of Adele C Radke

Estate of Mrs Nancy Rauchle

Estate of Alfred "Snow" & June

Grace Rawnsley

Estate of John & Joan Smith

Estate of Mrs Joyce Smith

Estate of Mrs Lucie Spatz

## Community

### Emeritus (\$250,000+)

Diggers Dozen Volunteers

### Mastery (\$100,000+)

Civic Solutions

Kedron-Wavell Sub Branch RSL &

Kedron Wavell Services Club Inc

NFIA (National Fire Industry  
Association) Patron's Walk for  
Charity

Pacific Golf Club

War Widows Guild of Australia  
(QLD) Inc

### Visionary (\$50,000 +)

Gill's Old Bastards

Greenbank RSL Sub-Branch &

Greenbank RSL Services Club Inc.

Greenslopes Private Hospital  
Volunteers

Qld Ex-Prisoner Of War Association

### Innovator (\$10,000 +)

Alma Williams & Friends

City of Brisbane Consistory No 1 A  
& AS Rite of Freemasonry

Clarries Green

Coorparoo & Districts RSL Sub  
Branch

Greenbank RSL Sub-Branch  
Women's Auxiliary

Redlands RSL

Rotary Club of Carindale

RSL Pioneer-Fitzroy-Highlands  
District Branch Inc.

Sherwood-Indooroopilly RSL Sub  
Branch

Sherwood Services Club Inc.

Stephens RSL Sub Branch

Walking on Sunshine

Womens Interest Group Society

Wynnum RSL Services Memorial  
Club

## Individual

### Emeritus Plus (\$250,000 +)

Blair & Joy Smith and Joanne Usher

### Emeritus (\$100,000 +)

Mrs Norma Jean Bracken

John & Elaine Feddersen

### Mastery (\$50,000 +)

The Barnett Family

Prof Darrell Crawford

Maria & Angelo Doukas

Mr & Mrs Brett & Zahra Godfrey

Pearl Logan, Lyn Unsworth & The  
Logan Family Foundation

Mr Bob Ney

Dr Rowland Noakes

Marjorie Trundle

### Visionary (\$25,000 +)

Jeffrey Boyling

Mrs Betty Buising

Dr Christopher & Simone Layton

Miria, Mike, Rewiti & Tua Ross

Anne & Brian Thornton

Roger & Marjorie Trundle

### Innovator (\$5,000 +)

The Airey Family

Mr Rolf Albrecht

Terry and Camilla Barker

Dr L Barrett

Mr Leslie A Batros

Mr John Beattie

Mr & Mrs Bernard and June Berry

Dr A Bofinger

Dr R Bach & Dr C Boothroyd

Mrs Mary & Mr Wally Boydell

The Broderick Family

Mrs Margaret Brodie

Mr Malcolm Broomhead

John William Burrows

Mr Vivian Byatt

Dr Lillian Cameron

Ian Chappell

Rick and Sue Chisholm

David & Eileen Cilento

Peter & Sandra Clarke

Assoc Prof David Colquhoun

Bil Colthurst

Mrs Joan Evelyn Court

Douglas & Helen Cowlshaw

Mr Douglas Cranstoun

Mr Peter Darmody

Mr & Mrs Willam & Lynette Deacon

Dr Jeff Deslandes

Ms Helen du Frocq

Ronald Dutton

Dr Anna Erian

Dr Mark Erian

Dr Stephen Fine

Mr & Mrs D Fort

Mrs Jane Francis

Raymond and Veronica Freier

Mr Colin Garrett

Dr John Gibson

Mr Cyril Gilbert OAM POW Changi

Mr & Mrs Geoff & Helen Glanville

Mr Cyril Golding

Prof Emeritus Richard D Gordon AO

Mr Keith & Mrs Olive Gore

Mr G. M. Grant

Dr Trevor Gray

Mr & Mrs Lloyd & Sharon Grundy

Dr Ross Gurgo

Dr Bruce Hall

Mr Robin Harvey

Steve & Julie Hearn

Mrs Patricia Hemsley

Dr Eileen Heyne & Dr Imre Kalas

Dr P Iocavella

The Irving/Legerton Families

Mr & Mrs Norma and Robert James

Dr R Kennedy

Dr N Kewal

Mr A Kinkade

Mr T Kinnane

Dr P Kortlucke

Bruce & Wendy Levien

Keong Lim

Dr A Majumdar

Freda Mangano

Wayne & Renee McAuliffe

Ken McDonald

Mr David McDougall POW Changi

Dr Glenda McLaren

Mr James McNeil

Petra Milaudi

Dr B Moore

Mr & Mrs Ken Naramura

Assoc Prof A Nicol

Assoc Prof D Nicol

Professor Andreas Obermair

George O'Kane

Kevin & Miriam O'Shea

Mr Mark Page

W.G. Patrick

EK & JO Pearson

Kevin & Barbara Petersen

Robin Pittar

Mrs Jean Pockett

Dr G Powell



# Acknowledgment

Dr J Preston  
Dr Kirsten & Dr Chris Price  
Dr S Rahman  
Dr J Reddrop  
Mr Edward Rigden  
Dr D Rosengren  
Roy Ryan  
Henry & Judi Scheuber  
Dr P Sharwood OAM RFD  
Mrs Betty Smith  
Ms Sheila B Smith  
Dr Lynda Spelman  
Mrs Anne Stanton  
Assoc Prof C Steadman  
Professor Michael Stowasser  
Assoc Prof Christopher Strakosch  
Dr Katherine Stuart  
Mr Nichalos (Pepper) & Mrs Maria Taifalous  
Mrs Jean Thompson  
Mrs Gwendoline C Trimble and WOFF J. "Bushy" Trimble A33761  
Mrs Joye Trundle  
Mr & Mrs Nicholas and Eugenia Vallianos  
Ronald J Vellacott  
Dr G Wagner  
Dr P Waterhouse  
Dr Noela Whitby AM & Prof Michael Whitby  
Dr P Whiting  
Mrs Alma Williams  
Mr & Mrs John & Leone Wilson  
Dr Glen & Mrs Susan Wood  
Stephen and Christine Went

## In Memoriam

Nulma & Russell Ball  
Murray Alexander Barnett  
Keith and Marjorie Boyling  
Brian John Brandenburg  
Delia Helen Cameron  
Olga Clarke  
Mrs Gert Francis  
Mr John Leslie Harrison  
Mr Lou Jurasko  
Henry James Elly Kinder (AE2, ex POW)  
(Buick) Ross Kinder (8th Division, ex POW)  
Cecil Gordon Lansdown  
Lynda Loughton  
Rhonda Linsdell  
The Miers Family  
Mrs Gemma Minto  
Mrs Bernadette Ney  
Lance & Eileen Ninnies  
Mr Jack Oliphant  
Gilbert Stanley Rider  
David Shepherdson  
Col Shields  
Mr John Dalglish Smith  
Mr Leslie Francis Smith (ex P.O.W)  
Peter H Solomon  
Mr Michael Storah  
Darryl Sugars  
Gordon Symes  
Wayne George Thomas  
Thomas Edwin Titmarsh 2/25th PoW  
Kuang-Liang Wu  
Mrs May Young

## Cyril Gilbert Testimonial Fund

The Cyril Gilbert Testimonial Fund was established to fight the impact of cancer. The following donors have united to bring the fund to a level where it makes a truly impactful difference in cancer care:

### Diamond (\$100,000+)

Mark Kelly

### Platinum (\$50,000+)

Assoc. Prof Victoria Atkinson  
Greenslopes Private Hospital  
Greenslopes Private Hospital Volunteers  
Mr Paul Ramsay AO  
The QLD Ex Prisoner of War Association  
Mr & Mrs Blair & Joy Smith & Mrs Joanne Usher

### Gold (\$25,000+)

Dr Pretoria Bilinski  
Marjorie & Keith Boyling  
Mrs Colleen Makhecha  
RSL Queensland

### Silver 10K +

Nick and Lexie Amarandos  
Diggers Dozen Greenslopes Private Hospital  
Janet Hooper & Louise Sanderson  
Peta-Jane & Bruce Kemp

Mr Robert Peter Kemp  
Dr Phil Moon  
The Moon Family  
Sullivan Nicolaides Pathology  
Alma Williams & Friends

### Bronze 5K +

Neil Mackay Barker  
Mr Ian Flamank  
Mr Cyril Gilbert OAM  
The Irving Legerton Families  
Mr Richard Lizzio  
Margaret McNickle  
Ms Carmel Monaghan  
Associate Prof. Andrew Nicol  
Helen Parker & Betty Croft  
Redlands RSL  
Mr Pat Welsh  
Anne Marie & Paul Wright

## GPH Cancer Wellness Program

### Founding Supporters

Blair Smith & Joanne Usher

### Champions (\$5,000+)

Les Batros  
Peta-Jane Kemp  
Premier Fire Pty Limited  
KPU's The Right Note  
Rotary Club of Carindale



# Financial Highlights 2019/2020

## As a foundation that does not receive government funding, GMRF relies on the generous support of our community.

We are incredibly grateful to the 1,010 donors who gave to our work during the 2019/2020 Financial Year. We received close to \$2 Million in funding from our individual and business donors, fundraisers and Discovery Partners. This level of support has enabled GMRF to maintain a strong financial position through the Coronavirus pandemic, continuing our progress.

We strive to repay the generosity of our community by ensuring every donation goes directly to innovative medical research and life-changing support initiatives. We pride ourselves on our low operating costs and efficient fundraising and administrative units. These expenses are offset by the in-kind support of Greenslopes Private Hospital and revenue from our Clinical Trials Unit.

You can access GMRF's Audited Financial Statement 2019/2020 at [bit.ly/GMRF-Financial-Statement-2020](https://bit.ly/GMRF-Financial-Statement-2020)



*"Despite the challenges 2020 has brought, the generosity of our supporters allowed the Foundation to maintain a sound financial position. Most importantly, it has enabled our research initiatives and programs to progress. For that we are very grateful." Jane O'Brien, GMRF Chief Operating Officer.*

# Supporting GMRF

Medical research is made possible by the generous support of our community. If you've been inspired by the difference we can make together through medical research, there are a number of ways you can get involved:

## Donate

Your donation can change lives! Talk to one of our development team for the ways you can support research or visit [www.gallipoliresearch.com.au](http://www.gallipoliresearch.com.au) to make a donation.

## Become a Regular Giver

Regular donations are essential for us to plan ahead for future initiatives, secure in the knowledge of regular financial support. GMRF Regular Givers receive an itemised tax receipt for all donations each year, allowing you to easily process your tax return.

## Become a Discovery Partner

Our Discovery Partners are committed and generous supporters who enable us to reach for even bigger goals in our quest for new treatments and breakthroughs. We are proud to display the names of our individual, community and corporate Discovery Partners on the GMRF honour boards, located at Greenslopes Private Hospital.

## Memorial Gifts

Memorial donations can be made to the GMRF in lieu of floral tributes. Memorial gift envelopes are available from the Foundation Office or can be requested via your funeral director.

## Leaving a Gift in your Will

Leaving a gift in your Will is one of the most significant ways you can assist our work and leave a lasting legacy for future generations. After considering family and friends, you might consider making a provision in your Will to support GMRF and become one of our Future Discovery Partners. Contact us on 07 3394 7284 for an obligation-free chat or to request a brochure with more information.

## Community Fundraising

GMRF relies on the amazing efforts of local groups to raise funds in their community. Get in contact with us to find out about how you can set up a community fundraising event or get your community group involved with supporting our research.

## Stay in touch

There's always a lot happening here at GMRF and we love to keep our community of supporters up-to-date on our impact. Visit the GMRF website to sign up to our Tribute Newsletter or follow us on Facebook or LinkedIn.

## Get in contact

To find out more about our work and how you can support us, get in touch with the GMRF Development Team. Phone: 07 3394 7284

Email: [enquiries.GMRF@ramsayhealth.com.au](mailto:enquiries.GMRF@ramsayhealth.com.au) | Web: [www.gallipoliresearch.com.au](http://www.gallipoliresearch.com.au)

Visit us: Greenslopes Private Hospital, Lower Lobby Level, Admin Building.




**Emma Bryant**

Director of  
Development




**Andrew Cramb**

Communications  
& Engagement  
Specialist



**Tracey Lowe**

Community  
Engagement  
& Fundraising  
Coordinator



**Lisa Clifford**

Foundation  
Administrator

# Appendix 2019/2020



**Veteran Mental Health Initiative**  
Research to restore lives

## Manuscripts

Rosenbaum, S., Morell, R., Abdel-Baki, A., Ahmadpanah, M., Anilkumar, T. V., Baie, L., Bauman, A., Bender, S., Boyan Han, J., Brand, S., Bratland-Sanda, S., Bueno-Antequera, J., Camaz Deslandes, A., Carneiro, L., Carraro, A., Castañeda, C. P., Castro Monteiro, F., Chapman, J., Chau, J. Y., Chen, L. J., ... Ward, P. B. (2020). Assessing physical activity in people with mental illness: 23-country reliability and validity of the simple physical activity questionnaire (SIMPAQ). *BMC psychiatry*, 20(1), 108.

Gilmour, John & Romaniuk, Madeline. (2020). Factor structure of posttraumatic stress disorder (PTSD) in Australian Vietnam Veterans: confirmatory factor analysis of the Clinician-Administered PTSD Scale for DSM-5. *Journal of Military, Veteran and Family Health*. e20180042. 10.3138/jmvfh.2018-0042.

## Manuscripts under review

Romaniuk M, Fisher G, Kidd, C and Batterham, P. Assessing Psychological Adjustment and Cultural Reintegration After Military Service: Development and Psychometric Evaluation of the Post-Separation Military-Civilian Adjustment and Reintegration Measure (M-CARM). Under review with *BMC Psychiatry* or *Frontiers in Psychology*.

Theal, R, Romaniuk M & Jessica Kerin, Psychosocial outcomes of Australian male and female ex service personnel following participation in peer-led adventure-based therapy. Under review with *Journal of Veterans Studies*

Theal, R, Lawford, B, Gibson J , Mellor, R and McLeay, S, Psychotropic Polypharmacy in Australian Vietnam War Veterans with post-traumatic stress disorder: a descriptive cohort study. Under review with *BMJ*.



## Manuscripts

5



## Invited Presentations

12



## Students

4



# Appendix 2019/2020



**GMRF Liver Research Unit**  
Research to restore lives

## Published Manuscripts

Huang I-T, Dhungel B, Shrestha R, Bridle KR, Crawford DHG, Jayachandran A, Steel JC. Spotlight on Bortezomib: Potential in the treatment of hepatocellular carcinoma. Expert Opinion on Investigational Drugs 2019; 28(1): 7-18.

Kanda T, Lau GKK, Wei L, Moriyama M, Yu ML, Chuang WL, Ibrahim A, Lesmana CRA, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Dokmeci AK, Mamun-Al-Mahtab, McCaughan GW, Wasim J, Crawford DHG, Kao JH, Yokosuka O, Sarin SK, Omata M. APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? Hepatology International 2019 Mar;13(2):103-109.

Núñez KG, Frank A, Gonzalez-Rosario J, Galliano G, Bridle K, Crawford D, Seal J, Abbruscato F, Vashistha H, Thevenot PT, Cohen AJ. Interleukin-33 / Cyclin D1 imbalance in severe liver steatosis predicts susceptibility to ischemia reperfusion injury. PLoS One. 2019 Apr 29;14(4):e0216242.

Kanda T, Lau GKK, Wei L, Moriyama M, Yu ML, Chuang WL, Ibrahim A, Lesmana CRA, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Kadir Dokmeci A, Mamun-Al-Mahtab, McCaughan GW, Wasim J, Crawford DHG, Kao JH, Ooka Y, Yokosuka O, Sarin SK, Omata M. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hepatology International. 2019 Nov;13(6):649-661.


Y Xie, Y Huang, Q Ruan, H Wang, X Liang, Z Hu, X Li. Impact of Tumor Site on Lymph Node Status and Survival in Colon Cancer. Journal of Cancer 2019, 10 (11): 2376.

C Yang, X Mi, H Su, J Yang, Y Gu, L Zhang, W Sun, X Liang, C Zhang. GE11-PDA-Pt@ USPIOs nano-formulation for relief of tumor hypoxia and MRI/PAI-guided tumor radio-chemotherapy. Biomaterials science 2019, 7 (5): 2076-2090.



**Manuscripts**

**24**



**Abstracts / Posters**

**3**



**Invited  
Presentations**

**6**



**Students**

**5**

# Appendix 2019/2020



**GMRF Liver Research Unit**  
Research to restore lives

CM Nastiti, Y Mohammed, KC Telaprolu, X Liang, JE Grice, MS Roberts, HAE Benson. Evaluation of quantum dot skin penetration in porcine skin: effect of age and anatomical site of topical application. *Skin Pharmacology and Physiology* 2019, 32(4): 1-10.

H Wang, H Lu, H Yang, X Zhang, EW Thompson, MS Roberts, Z Hu, X Liang, X Li. Impact of Age on Risk of Lymph Node Positivity in Patients with Colon Cancer. *Journal of Cancer* 2019, 10(9): 2102.

Shrestha R, Bridle KR, Crawford DHG, Jayachandran A. Immune checkpoint blockade therapies for HCC: current status and future implications. *Hepatology Research* 2019; 5:32.

Zhang, H Su, H Wang, Q Li, X Li, C Zhou, J Xu, Y Chai, X Liang, L Xiong, C Zhang, Tumor chemo-radiotherapy with rod-shaped and spherical gold nano probes: shape and active targeting both matter. *Theranostics* 2019, 9: 1893-1908.

W Xiao\*, TIP Green\*, X Liang\*, RC Delint, G Perry, MS Roberts, KL Vay, CR Back, R Ascione, H Wang, PR Race, AW Perriman Designer artificial membrane binding proteins to direct stem cells to the myocardium. *Chemical Science* 2019, 10 (32): 7610-7618.

T Chen, S Tu, H Wang, X Liu, F Li, W Jin, X Liang, X Zhang, J Wang. Computer-aided diagnosis of gallbladder polyps based on high resolution ultrasonography. *Computer methods and programs in biomedicine* 2020, 185: 105118.

S Wei, J Chen, Y Huang, Q Sun, H Wang, X Liang, Z Hu, X Li. Identification of hub genes and construction of transcriptional regulatory network for the progression of colon adenocarcinoma hub genes and TF regulatory network of colon adenocarcinoma. *Journal of cellular physiology* 2020, 235 (3): 2037-2048.

Jayachandran A, Shrestha R, Bridle K and Crawford D. Association between Hereditary Hemochromatosis and HCC: a comprehensive review. *Hepatology Research* 2020; 6:8.

Shrestha R, Bridle KR, Crawford DHG, Jayachandran A. TNF- $\alpha$ -mediated epithelial-to-mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma. *Molecular Medicine Reports*. 2020; 21(4):1849-1860.

Ruan Q, Wang H, Burke LJ, Bridle KR, Li X, Zhao CX, Crawford DHG, Roberts MS, Liang X. Therapeutic modulators of hepatic stellate cells for hepatocellular carcinoma. *International Journal of Cancer*. 2020 Feb 3. doi: 10.1002/ijc.32899. In Press.

J Yang, M Hou, W Sun, Q Wu, J Xu, L Xiong, Y Chai, Y Liu, M Yu, H Wang, ZP Xu, X Liang, C Zhang. Sequential PDT and PTT using dual-modal single-walled carbon nanohorns synergistically promote systemic immune responses against tumor metastasis and relapse. *Advanced Science*. 2020, 2001088. DOI: 10.1002/adv.202001088.

LJ Spannenburg, M Cook, A Brooks, S Wei, X Li, X Liang, W Gao, H Wang. Surgical Outcomes of Colonic Stents as a Bridge to Surgery versus Emergency Surgery for Malignant Colorectal Obstruction: A Systematic Review and Meta-analysis of High Quality Prospective and Randomised Controlled Trials. *European Journal of Surgical Oncology* (Accepted 2020)

# Appendix 2019/2020



**GMRF Liver Research Unit**  
Research to restore lives

Y Zhang, H Wang, T Chen, H Wang, X Liang, Y Zhang, J Duan, S Qian, K Qiao, L Zhang, Y Liu, J Wang. C24-ceramide drives gallbladder cancer progression through directly targeting PIP4K2C to facilitate mTOR signaling activation. *Hepatology* (Accepted 2020).

J Yan, H Feng, H Wang, F Yuan, C Yang, X Liang, W Chen, J Wang. Hepatic artery classification based on three-dimensional CT. *British Journal of Surgery* 2020. Doi:10.1002/bjs.11458.

Wang H, Burke LJ, Patel J, Tse BWC, Bridle KR, Cogger VC, Xinxing Li, Liu X, Yang H, Crawford DHGH, Roberts MS, Gao W, Liang X. Imaging-based vascular-related biomarkers for early detection of acetaminophen-induced liver injury. *Theranostics*, 2020; 10(15):6715-6727.

Reiling J, Butler N, Simpson A, Hodgkinson P, Campbell C, Lockwood D, Bridle K, Santrampurwala N, Britton L, Crawford D, Dejong C, Fawcett J. Assessment and transplantation of orphan donor livers - a "back-to-base" approach to normothermic machine perfusion. *Liver Transplantation*, 2020 Jul 18. doi: 10.1002/lt.25850; In Press.

R Baidya, DHG Crawford, J Gautheron, H Wang, KR Bridle. Necroptosis in hepatosteatotic ischaemia-reperfusion injury. *International Journal of Molecular Sciences*, 2020, In Press.

DS Barkauskas, G Medley, X Liang, YH Mohammed, CA Thorling, H Wang, Haolu, MS Roberts. Using in vivo multiphoton fluorescence lifetime imaging to unravel disease-specific changes in the liver redox state. *Methods and Applications in Fluorescence*, 2020, 8 3. doi:10.1088/2050-6120/ab93de


## Published Abstracts

R Shrestha, K Bridle, L Cao, D Crawford, A Jayachandran. Tumor necrosis factor-alpha promotes epithelial-to-mesenchymal transition and expression of immune checkpoint molecules in hepatocellular carcinoma. *Journal of Gastroenterology and Hepatology* 2019. 34(S2):51.

R. Baidya, L Jaskowski, J Gautheron, A Jayachandran, H Wang, P Thevenot, A Cohen, D Crawford, K Bridle. Attenuation of receptor-interacting protein kinase3 (RIPK3) and mixed lineage kinase domain like pseudokinase (MLKL) blocks the TRIF-RIPK3-MLKL-driven necroptotic cell death in steatotic hepatocytes undergoing ischemic injury. *Journal of Gastroenterology and Hepatology* 2019. 34(S2):47.

Cao L, Shrestha R, Bridle KR, Crawford DHG and Jayachandran A. Enrichment of multiple Immune Checkpoints in Cholangiocarcinoma Cancer Stem Cells. *Journal of Gastroenterology and Hepatology* 2019. 34(S2):35

# Appendix 2019/2020



**GMRF Respiratory Unit**  
Research to restore lives

## Published Manuscripts

Thomson RM, Furuya-Kanamori L, Coffey C, Bell SC, Knibbs LD, Lau CL. Influence of climate variables on the rising incidence of nontuberculous mycobacterial (NTM) infections in Queensland, Australia 2001–2016. *Science of The Total Environment*. 2020;740:139796.

Kurz SG, Zha BS, Herman DD, Holt MR, Daley CL, Ruminjo JK, Thomson CC. Summary for Clinicians: 2020 Clinical Practice Guideline Summary for the Treatment of Nontuberculous Mycobacterial Pulmonary Disease. *Ann Am Thorac Soc* 2020 (In Press)

Ratnatunga C, Lutzky V, Kupz A, Doolan D, Reid D, Bell S, et al. The rise of nontuberculous mycobacterial lung disease. *Frontiers in Immunology*. 2020.

Aliano D, Thomson R. The epidemiology of extra-pulmonary nontuberculous mycobacterial infection in a pediatric population. *Paediatr Infect Dis J*. 2020;39(8):671-7.

Visser SK, Bye PTP, Fox GJ, Burr LD, Chang AB, Holmes-

Liew C-L, et al. Australian adults with bronchiectasis: The first report from the Australian Bronchiectasis Registry. *Respiratory Medicine*. 2019;155:97-103.

Visser SK, Bye PT, Fox GJ, Burr LD, Chang AB, Holmes-Liew C-L, King P, Middleton PG, Maguire GP, Smith D, Thomson RM, Stroil-Salama E, Britton WJ, Morgan LC. Management of Australian Adults with bronchiectasis in Tertiary Care: evidence- based or access driven? *Lung* 2019;197(6):803-810

Thomson R. Inhaled therapies for NTM disease- The way forward? *J Cyst Fibrosis*. 2019;18:581-3.

Stockwell RE, Chin M, Johnson GR, Wood ME, Sherrard LJ, Ballard E, et al. Transmission of bacteria in bronchiectasis and chronic obstructive pulmonary disease: Low burden of cough aerosols. *Respirology*. 2019;24(10):980-7.

Holt MR, Kasperbauer SH, Daley CL. Serial sputum induction in nontuberculous mycobacterial pulmonary disease. *Eur Respir J* 2020; 55: 1902196 [https://doi.org/10.1183/13993003.02196-2019].




## Manuscripts

**13**



## Abstracts

**4**



## Invited Presentations

**11**



## Students

**5**



# Appendix 2019/2020



Kwak N, Dalcolmo MP, Daley CL, Eather G, Hasegawa N, Koh W-J, et al. Nontuberculous mycobacteria infections: would there be pharmacodynamics without pharmacokinetics? *European Respiratory Journal*. 2019;54(5):1901806.

Kwak N, Dalcolmo MP, Daley CL, Eather G, Gayoso R, Hasegawa N, et al. Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis. *European Respiratory Journal*. 2019;54(1):1801991.

Holt MR, Miles JJ, Inder WJ, Thomson RM. Exploring immunomodulation by endocrine changes in Lady Windermere syndrome. *Clinical & Experimental Immunology*. 2019;196(1):28-38.

Gibson J, Baird T, Pandey S, Tolson C, Coulter C, Eather G, et al. The clinical significance of Mycobacterium triplex. *RespMed*. 2019;159.

## Published Abstracts

Holt M, Inder W, Miles J, Thomson R. The Distinctive Body Composition and Endocrine Profile of Women with Nontuberculous Mycobacterial Pulmonary Disease. B106 BREAKTHROUGHS IN NTM DIAGNOSIS AND TREATMENT. p. A4354-A.

Flume PA, Thomson R, Brown-Elliott BA, R.J. Wallace J, Griffith DE, Pennings LJ, et al. Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease: Effect of Baseline Amikacin and Clarithromycin Susceptibility on Culture Conversion. C16 NTM DISEASE - NEW DATA AND CHANGING PARADIGMS. p. A4494-A.

Stockwell R, Leong L, Wheeler N, Bryant J, Wood M, Sherrard L, Thomson R, Carter R, Tolson C, Rogers G, Wainwright C, Parkhill J, Floto R, Bell S. Alternative transmission pathways of Mycobacterium abscessus group (MABS) respiratory infections. TO 002 *Respirology* 2020;25(S1):22-110.

Kapur N, Stroil-Salama E, Holmes-Liew C, King P, Middleton P, Maguire G, Smith D, Thomson R, Morgan L, McCallum G, Owens L, Chang A. Australian children with bronchiectasis: the first report in children from the Australian bronchiectasis registry. *Respirology* 2020;25(S1):22-110.

# Appendix 2019/2020



**GMR Clinical Trials Unit**  
Research to restore lives

## CLINICAL TRIALS PUBLICATIONS

### Published Manuscripts

**Atkinson V**, Sandhu S, Hospers G, Long G, Aglietta M, Ferrucci P, Tulyte S, Cappellini G, Soriano V, Sayed A, Poprach A, Cesas A, Rodriguez-Abrue S, Lau M, ed Jong E, Legenne P, Stein D, King B and van Thienen J. Dabrafenib plus trametinib is effective in the treatment of BRAF v600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II) **Melanoma Research** 2020 June 30 (3) p261-7  
Doi:10.1097/CMR0000000000000654

Dummer R, Brase J, Garrett J, Campbell C, Gasal E, Squires M, Gusenleiter D, Santinami M, **Atkinson V**, Mandala M, Chiarion-Sileni, Flaherty K, Larkin J, Robert C, Kefford R, Kirkwood J, Hauschild A, Schadendorf D and Long G. Adjuvant Dabrafenib plus Trametinib versus placebo in patients with resected stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. **Lancet Oncology** Published online January 2020 DOI.org/10.1016/S1470-2045(20)30062-0

Schadendorf D, Hauschild A, Santinami M, **Atkinson V**, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Lesimple T, Plummer R, Schachter J, Dasgupta K, Manson S, Koruth R, Mookerjee

B, Kefford R, Dummer R, Kirkwood JM, Long GV. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF(V600E) or BRAF(V600K) mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. **Lancet Oncol.** 2019 May;20(5):701-710. doi: 10.1016/S1470-2045(18)30940-9. Epub 2019 Mar 27.

Antoni Ribas, Donald Lawrence, **Victoria Atkinson**, Sachin Agarwal, Wilson H Miller Jr, Matteo S Carlino, Rosalie Fisher, Georgina V Long, F Stephen Hodi, Jennifer Tsoi, Catherine S Grasso, Bijoyesh Mookerjee, Qing Zhao, Razi Ghor, Blanca Homet Moreno, Nageatte Ibrahim, Omid Hamid. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. **Nat Med.** 2019 Jun;25(6):936-940. doi: 10.1038/s41591-019-0476-5. Epub 2019 Jun 6. PMID: 31171879 DOI: 10.1038/s41591-019-0476-5

Ezra E W Cohen, Denis Soulières, Christophe Le Tourneau, José Dinis, Lisa Licitra, Myung-Ju Ahn, Ainara Soria, Jean-Pascal Machiels, Nicolas Mac, Raneer Mehra, Barbara Burtneess, Pingye Zhang, Jonathan Cheng, Ramona F Swaby, Kevin J Harrington, **KEYNOTE-040 investigators**: Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study **Lancet** 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30. **\*\* Dr Margaret McGrath**



## Publications

5



## Invited Presentations

4



## Affiliated Medical Officers

15



# Thanks to our community — changing lives for 15 years!





#### **Gallipoli Medical Research Foundation**

C/o Greenslopes Private Hospital

Administration Building

Newdegate Street, Greenslopes QLD 4120

Email: [enquiries.gmrf@ramsayhealth.com.au](mailto:enquiries.gmrf@ramsayhealth.com.au)

Phone: (07) 3394 7284

Website: [www.gallipoliresearch.com.au](http://www.gallipoliresearch.com.au)

Facebook: Gallipoli Medical Research Foundation

Linked In: Gallipoli Medical Research Foundation